Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Pharmacy

Implementing pharmacogenomics-driven supportive care for stem cell transplant recipients 3:37
Implementing pharmacogenomics-driven supportive care for stem cell transplant recipients
Justin Arnall • 21 Feb 2023
The role of the pharmacist in interpreting & applying PGx results in transplant recipients 4:25
The role of the pharmacist in interpreting & applying PGx results in transplant recipients
Justin Arnall • 21 Feb 2023
Impact of belumosudil on tacrolimus & sirolimus pharmacokinetics in patients with chronic GvHD 4:50
Impact of belumosudil on tacrolimus & sirolimus pharmacokinetics in patients with chronic GvHD
Rebecca Gonzalez • 16 Feb 2023
Best practices for vaccines after SCT and cellular therapy & the role of pharmacists in this process 4:49
Best practices for vaccines after SCT and cellular therapy & the role of pharmacists in this process
Susie Long • 9 Feb 2023
Nursing track: pharmacy updates 2:13
Nursing track: pharmacy updates
Susie Long • 9 Feb 2023
Incidence & factors associated with vitamin C deficiency in pediatric HCT recipients 4:01
Incidence & factors associated with vitamin C deficiency in pediatric HCT recipients
Susie Long • 9 Feb 2023
Phase I study of HPN217 in patients with R/R multiple myeloma 3:06
Phase I study of HPN217 in patients with R/R multiple myeloma
Al-Ola Abdallah • 11 Dec 2022
Phase I study of neihulizumab in patients with SR-aGvHD or TR-aGvHD 4:38
Phase I study of neihulizumab in patients with SR-aGvHD or TR-aGvHD
Sameem Abedin • 8 Dec 2022
AML: mutant IDH1 inhibitor HMS-101 2:51
AML: mutant IDH1 inhibitor HMS-101
Michael Heuser • 25 Oct 2019
MM: The battle for new drugs 1:18
MM: The battle for new drugs
Jonathan Keats • 13 Sep 2019
The need for academic and pharmaceutical collaboration in drug development 9:19
The need for academic and pharmaceutical collaboration in drug development
Jay Bradner et al.
Self-administration of bortezomib in multiple myeloma: results from Cardiff 2:18
Self-administration of bortezomib in multiple myeloma: results from Cardiff
Tanya Burton
Accelerating clinical trials in transplantation 2:24
Accelerating clinical trials in transplantation
Charles Craddock • 12 Oct 2018
Regulatory approval of CPX-351 for secondary AML 2:11
Regulatory approval of CPX-351 for secondary AML
Charles Craddock • 12 Oct 2018
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML 2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman • 12 Oct 2018
The switch to biosimilar rituximab at UCH: 12 months on 0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman • 12 Oct 2018
The content of VJHemOnc is intended for healthcare professionals